Effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors on metabolic parameters in patients with type 2 diabetes: A chart-based analysis

Effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors on metabolic parameters in patients with type 2 diabetes: A chart-based analysis - Effects of SGLT2 inhibitors in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020314

Enrollment

Registered

2015-12-22

Start date

2015-12-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with type 2 diabetes, who had been prescribed SGLT2 inhibitors for 1 month or longer between April 2014 and November 2015

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
body weight, blood pressure, plasma glucose, HbA1c, serum low-density lipoprotein-cholesterol (LDL), triglyceride (TG), high-density lipoprotein-cholesterol (HDL), non-HDL-cholesterol (non-HDL), aspartate aminotransferase (AST), alanine aminotransferase (ALT), eGFR	—

Countries

Japan

Contacts

Public ContactHisayuki Katsuyama

National Center for Global Health and Medicine Kohnodai Hospital Department of Internal Medicine

katsuyama-hs@umin.org+81-47-272-0034

Outcome results